Actavis UK’s ‘Excessive’ Price Hikes Targeted In Latest Competition Inquiry

The UK competition authority has provisionally found that Actavis UK imposed “excessive” price rises on its generic version of hydrocortisone for the life-threatening condition, adrenal insufficiency. The case has similarities to the price increases on phenytoin capsules, for which Pfizer and Flynn Pharma were recently fined.